FDA Releases Draft Guidance on Adaptive Design Clinical Trials for Drugs and Biologics

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document that provides information and advice on adaptive design clinical trials, which are used in the development of drugs and biologics, to help sponsors plan and conduct these studies efficiently and facilitate a smoother review process by the FDA.